Solasia Pharma

Solasia Pharma K.K. is a Tokyo-based company focused on developing and distributing pharmaceuticals and medical devices for oncology in Asia. Established in 2006, Solasia offers products such as episil oral liquid for pain control and relief, and Sancuso, a transdermal system that administers granisetron to treat chemotherapy-induced nausea and vomiting. The company is advancing its clinical pipeline with SP-02, a mitochondrial-targeted agent currently in Phase II trials for various hematologic and solid tumors, and SP-04, which has completed Phase IIb trials for chemotherapy-induced peripheral neuropathy. In addition to its drug development efforts, Solasia is involved in the import and export of medicines and medical equipment.